web analytics
4.7 C
Tuesday, November 29, 2022

Todays Equity Focus is Ekso Bionics Holdings, Inc. (OTCBB: EKSO)

Ekso Bionics Holdings, Inc. (OTCBB: EKSO) has continued to move lower in recent months since the $1.40 plus price tag it commanded back in November of last year. The stock has a long history of big moves running from just over $2 to highs over $8 a share last year.

EKSO trades on the OTCBB but the Company operates more like a Big Board Stock than a microcap. Since inception there has been no known promotion of EKSO yet the stock trades millions. As well the Company has the proven ability to raise large sums of money; EKSO went public through a reverse merger in January of last year, simultaneously raising $20.6 million through a bridge debt transaction.

Ekso Bionics Holdings, Inc. (OTC: EKSO) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company’s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Originally Berkeley Bionics, Ekso Bionics was founded in Berkeley, California in 2005. Since inception Ekso Bionics has forged partnerships with world-class institutions like UC Berkeley, received research grants from the Department of Defense and licensed technology to the Lockheed Martin Corporation.

The big story on EKSO started last October when they announced that they were selected by Boston Dynamics, now part of Google, to continue developing technologies for Defense Advanced Research Projects Agency’s (DARPA’s) Warrior Web Task A project.

Lockheed Martin is the exclusive contractor of the US military, EKSO is working with them in an attempt to provide exoskeletons for military purposes. Many EKSO investors are overlooking this opportunity. The military market could be the secondary market that not only raises awareness of EKSO’s bionic skeleton, but also advances the function of the technology.

For more info on EKSO Please Subscribe below, also you should know we have Something Huge Coming!

Back in August EKSO said ”Bionics is the study of biological functions and the development of artificial organs and body parts that are used as a replacement of the original part or organs. The bionic organs are designed in such a way so that they can imitate the functions of the organs in order to operate properly. The market is expected to grow during the forecast period due to the increasing demand for artificial organs in the healthcare sector. In addition, the aging population is resulting into multiple organ failure. This in return is creating a need for organ transplant.

However, the chance for getting a suitable donor for a transplant requires lot of time and thus reduces the chance of survival. The use of bionics part does not require time and these parts are designed to adjust with the body requirements. Furthermore, the bionics are also being applied in the defense sector in the form of exoskeleton suits which enables a soldier to carry heavy loads without reducing his or her speed in the battlefield.

On January 11 EKSO announced a new randomized comparative clinical trial is currently underway in Europe. The trial is called “The MOST Study” (Mobility improved after stroke when a robotic device was used in comparison to physical therapy) and is being initialized by Professor Dr. med. F. Hamzei, MD, MHBA, Chief physician of Department of Neurological Rehabilitation, Moritz Klinik. This study is investigating the impact of gait training with the Ekso GT(TM) on functional independence of 80 patients with impaired gait as a consequence of stroke, when compared to conventional physiotherapy alone.

“Based on our early observation, gait training with Ekso GT has shown to be a superior method over conventional physiotherapy techniques alone to improve rehabilitation of stroke patients,” said Professor Hamzei. “Stroke is one of the most common causes of chronic disability and can have long term debilitating effects. Intervening early and regularly with advanced assistive devices such as Ekso GT may significantly positively impact stroke patients’ overall motor recovery and help to regain or maintain their independence. That’s our hypothesis in the ongoing randomized controlled study”.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $84 million market valuation EKSO does have $25 million in the treasury, manageable debt and fast growing revenues. EKSO is also one of the most exciting stocks in small caps fast becoming a leader and pioneering the field of robotic exoskeletons, or wearable robots; their first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. As I said the Company has a proven ability to raise large sums of money and they already have their eye on a bigger exchange. We will be updating on EKSO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with EKSO.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in EKSO either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.